rethinkTHC Search
Menu
Study breakdown

Combining serotonin and cannabinoid drugs improved a schizophrenia-related brain function in mice

Animal StudyPreliminary evidence
The takeaway

Combining a serotonin 5-HT2A blocker with a CB1 receptor blocker improved prepulse inhibition (a brain function disrupted in schizophrenia) more than either drug alone in mice.

Psychopharmacology researchers, schizophrenia drug developers, and neuroscientists.

Volinanserin + rimonabant combination improved PPI; neither cannabinoid drug alone did

What the researchers found

Neither the CB1 agonist WIN 55,212-2 nor the CB1 inverse agonist rimonabant alone affected prepulse inhibition (PPI) or blocked MK-801-induced PPI deficits. However, combining the 5-HT2A antagonist volinanserin with rimonabant significantly improved PPI in both normal and MK-801-treated mice, suggesting a synergistic interaction between serotonin and cannabinoid systems.

Why it matters

Current antipsychotic medications have significant side effects. Finding that combined serotonin-cannabinoid modulation works better than either alone opens a new avenue for drug combination strategies in psychotic disorders.

The numbers in context

Volinanserin + rimonabant combination increased PPI in both control and MK-801-treated mice; neither cannabinoid drug alone affected PPI.

How the study worked

Animal study in male Swiss mice testing combinations of cannabinoid drugs (WIN 55,212-2, rimonabant) and serotonin drugs (8-OH-DPAT, volinanserin) in an MK-801-induced PPI disruption model relevant to schizophrenia.

What this study cannot tell us

Animal model; MK-801-induced PPI disruption is only one aspect of schizophrenia pathology; rimonabant has been withdrawn from clinical use due to psychiatric side effects; only male mice used.

How to read the evidence

Preliminary: animal behavioral pharmacology study with synthetic compounds.

When this study was published

Published 2020.

The bigger picture

This supports the idea that complex mental illnesses may respond better to multi-target drug approaches than single-mechanism treatments. The serotonin-endocannabinoid interaction could be particularly relevant for schizophrenia.

Questions still open

  • Could newer CB1 antagonists without rimonabant side effects achieve the same synergy? Would this combination approach work in human psychosis?

Common questions

What is prepulse inhibition?
A brain function where a weak stimulus reduces the startle response to a subsequent stronger stimulus. It is consistently disrupted in schizophrenia and used as a model for studying antipsychotic drug targets.
Why did the combination work but not the individual drugs?
The authors suggest that blocking CB1 receptors potentiated the effect of 5-HT2A blockade, implying these systems interact to control sensory gating processes disrupted in psychosis.

Read the original research

Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.

Psychopharmacology, 237(6), 1643-1655

Citation

Marques, Adriana M; Macena, Michele V; Cardoso, Aline R; Hammes, Camila S O; Pinheiro, Fernanda M L; Castro, Newton G; Neves, Gilda A. (2020). Effects of combined 5-HT2A and cannabinoid receptor modulation on a schizophrenia-related prepulse inhibition deficit in mice.. Psychopharmacology, 237(6), 1643-1655. https://doi.org/10.1007/s00213-020-05485-0

Explore the wider topic